| TA142 |
Anaemia (cancer-treatment induced) - erythropoietin (alpha and beta) and darbepoetin (TA142) |
|
-
-
Erythropoetin (alpha and beta) and darbepoetin for the treatment of cancer-treatment induced anaemia
Erythropoietin analogues with iron injections are recommended as a possible treatment for anaemia caused by cancer treatment only in:
- women receiving platinum-based chemotherapy for cancer of the ovaries who have a blood haemoglobin level of 8 g/100 ml or lower
- people who have very severe anaemia and cannot receive blood transfusions.
Healthcare professionals should not stop prescribing erythropoietin analogues for people who were already taking them when the guidance was issued. These people should be able to carry on taking erythropoietin analogues until they and their healthcare professionals decide that it is the right time to stop treatment.
We will consult on our review plans for this guidance in February 2009.
-
Other information
How this guidance was produced
Background information
This page was last updated: 12 December 2011
-
Guidance formats
- Web format
- Quick reference guide (PDF)
- Full Guidance (PDF)
- Patient version (MS Word)
- TA142 Analogau erythropoietin ar gyfer anemia a achosir gan driniaeth canser: deall canllawiau NICE (fformat MS Word)
Anaemia (cancer-treatment induced) - erythropoietin (alpha and beta) and darbepoetin
Guideline for patients and carers (PDF)
-
Implementation tools and resources
See this guidance in practice
Patient
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
NICE Guidance
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
Full Guidance
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.
